Antitrust & Competition Life Sciences Quarterly Update – Q3 2023

The FTC’s Amgen/Horizon Lawsuit Ends With a Whimper – We covered the FTC’s investigation into (and litigation challenging) Amgen’s $28.3 billion acquisition of rare disease specialist Horizon Therapeutics in our Q1 and Q2 updates….
By: Goodwin
Previous Story

Asset Tokenization Takes a Big Step Forward

Next Story

White House to issue AI rules for federal employees